# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Duke Kahanamoku (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML050-SYN-TD
- Date: 1957-04-13
- Fictional facility: St. Posthumous Health Center
- Fictional author: Kawika Lindgren-Morrison, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Two-week review after starting sacubitril-valsartan, carvedilol and empagliflozin. **S**

## History of present illness

Mr. Kahanamoku returns two weeks after starting carvedilol and empagliflozin and twelve days after his first dose of sacubitril-valsartan, taken as planned 36 hours after the last lisinopril. He feels better: he walks up the slope near his office without stopping, the ankle swelling has gone, and he sleeps flat. He has had no lightheadedness, cough, genital itching or burning on passing urine. His home weight is steady at 93.5 to 94 kg. Coronary angiography last week showed an old complete blockage of the main artery at the front of the heart, with collaterals, and only mild narrowing elsewhere; the cardiologist advised that opening it would not help the scarred muscle. He is ready for the second iron infusion. **S**

| Element | Detail |
|---|---|
| Function | Walks uphill without stopping; NYHA class II to III |
| Medicine effects | No lightheadedness, cough or genital infection |
| Angiography | Chronic total occlusion of the proximal left anterior descending artery; mild disease elsewhere; no revascularization |
| KCCQ-12 | 56, from 38 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Cardiovascular | Negative | No chest pain, palpitations, ankle swelling or lightheadedness |
| Respiratory | Negative | No cough; sleeps flat |
| Genitourinary | Negative | No genital itching or dysuria |

3 systems reviewed. **S**

## Current medications

- Aspirin 81 mg delayed-release oral tablet, one tablet daily **S**
- Atorvastatin 80 mg oral tablet, one tablet daily **S**
- Furosemide 40 mg oral tablet, one tablet every morning **S**
- Sacubitril 24 mg / valsartan 26 mg oral tablet, one tablet twice daily, first dose 36 hours after the last lisinopril **S**
- Carvedilol 6.25 mg oral tablet, one tablet twice daily with food **S**
- Empagliflozin 10 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating or drinking **S**
- Spironolactone 25 mg oral tablet, one-half tablet (12.5 mg) daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 118/72 mmHg; pulse 74 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 93.6 kg; BMI 27.3 kg/m². All vital signs are synthetic.

Sodium: 137 mmol/L; Potassium: 4.5 mmol/L; Creatinine: 1.16 mg/dL; eGFR (CKD-EPI 1952): 69 mL/min/1.73 m²; Glucose: 96 mg/dL; Magnesium: 2 mg/dL; KCCQ-12 overall summary: 56. All results are synthetic.

## Change since baseline

- Sodium: 138 mmol/L at baseline, 137 mmol/L at this visit **S**
- Potassium: 4.2 mmol/L at baseline, 4.5 mmol/L at this visit **S**
- Creatinine: 1.02 mg/dL at baseline, 1.16 mg/dL at this visit **S**
- eGFR (CKD-EPI 1952): 81 mL/min/1.73 m² at baseline, 69 mL/min/1.73 m² at this visit **S**
- Glucose: 102 mg/dL (high) at baseline, 96 mg/dL at this visit **S**
- Magnesium: 2 mg/dL at baseline, 2 mg/dL at this visit **S**
- KCCQ-12 overall summary: 38 at baseline, 56 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 118/72, pulse 74; weight 93.6 kg |
| Neck | Jugular venous pressure not raised |
| Cardiovascular | Regular rhythm; no S3; apical systolic murmur |
| Respiratory | Clear |
| Extremities | No edema; right radial access site healed |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Heart failure with reduced ejection fraction** (I50.22). Improving: NYHA class II to III, euvolemic, KCCQ-12 56 from 38. Potassium 4.5 mmol/L and creatinine 1.16 mg/dL (eGFR 69), a 7% rise, expected and acceptable. Blood pressure 118/72 and pulse 74 allow the next steps. **S**
   - Start spironolactone 12.5 mg daily (potassium below 5.0 and eGFR above 30).
   - Raise carvedilol to 6.25 mg twice daily.
   - Continue sacubitril-valsartan 24/26 mg, empagliflozin and furosemide 40 mg.
   - Metabolic panel at the review in two weeks, one to two weeks after spironolactone.
   - Sick-day rules reviewed again now that four medicines act on the kidney.
2. **Coronary artery disease** (I25.2). Chronic total occlusion of the left anterior descending artery feeding a scarred, thinned wall, with mild disease elsewhere: medical therapy, not revascularization, as the cardiologist advised. **S**
   - Continue aspirin 81 mg and atorvastatin 80 mg.
3. **Iron deficiency** (E61.1). First infusion two weeks ago without reaction. **S**
   - Second ferric carboxymaltose 750 mg infusion today.
   - Iron studies at about six months.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure and heart rate (seated and standing) | Every visit | Completed today | 118/72 mmHg, pulse 74; no orthostatic drop |
| Examination | Weight, volume status (jugular venous pressure, edema, lungs) and NYHA class | Every visit | Completed today | 93.6 kg; jugular venous pressure not raised; lungs clear; no edema; NYHA II to III |
| Laboratory | Metabolic panel (sodium, potassium, creatinine and eGFR) and magnesium | One to two weeks after starting or changing a diuretic, ARNI, MRA or SGLT2 inhibitor; then every three to six months | Completed today | About two weeks after sacubitril-valsartan and empagliflozin: sodium 137, potassium 4.5, creatinine 1.16 mg/dL (eGFR 69), magnesium 2.0 |
| Medication safety | Guideline-directed medical therapy: ARNI, evidence-based beta-blocker, MRA and SGLT2 inhibitor, toward target doses | Every two weeks during titration | Completed today | All four classes now started: spironolactone added and carvedilol raised today |
| Medication safety | SGLT2 inhibitor and ARNI: genital infection, volume depletion, hypotension and angioedema | Every visit | Completed today | None; sick-day rules reviewed |
| Survey | KCCQ-12 heart failure health status | At diagnosis, then every three to six months | Completed today | 56, from 38 |
| Imaging | Ischemic evaluation (coronary angiography) | At diagnosis of HFrEF with suspected coronary cause | Up to date | Done last week: chronic total occlusion of the proximal left anterior descending artery, mild disease elsewhere; no revascularization |
| Imaging | Echocardiogram | At diagnosis; repeat after three to six months of optimized therapy for device decisions, or with unexplained change | Not indicated | Diagnosis two weeks ago; repeat after three to six months of optimized therapy |
| Medication safety | Iron studies (ferritin, transferrin saturation) and intravenous iron | At diagnosis; after repletion and about yearly | Completed today | Second ferric carboxymaltose 750 mg infusion today |
| Examination | Primary-prevention ICD evaluation (and CRT if QRS is wide) | After at least 90 days of optimized therapy, and at least 40 days after a myocardial infarction | Due | After at least 90 days of optimized therapy |
| Referral | Cardiac rehabilitation for heart failure | When eligible: ejection fraction 35% or below, NYHA II to IV, six weeks of stable therapy and no procedure in six weeks | Due | Eligible from about six weeks after angiography and the last medicine start |
| Self-management | Self-care: daily weights, sodium, sick-day rules and symptoms to report | Every visit | Completed today | Weighs daily; less salted fish and shoyu; sick-day card given |
| Self-management | Culturally safe care: ʻohana involvement as he chooses; his own healing practices | Every visit | Completed today | He reviews decisions with his ʻohana at home as he chooses |

## Goal progress

- Euvolemia: no ankle swelling or orthopnea, with a steady dry weight. In progress; target 1957-04-27. **S**
- All four guideline-directed medicines at the highest doses he tolerates within three months. In progress; target 1957-09-28. **S**
- KCCQ-12 at least 20 points higher and NYHA class I to II within six months. In progress; target 1957-09-28. **S**
- Back in the ocean safely, swimming in calm water with a companion. In progress; target 1957-09-28. **S**
- LDL cholesterol below 70 mg/dL. In progress; target 1957-04-27. **S**

## Medication changes

- Stopped: Carvedilol 3.125 mg oral tablet, one tablet twice daily with food, starting the evening after the last metoprolol tartrate **S**
- Started: Carvedilol 6.25 mg oral tablet, one tablet twice daily with food **S**
- Started: Spironolactone 25 mg oral tablet, one-half tablet (12.5 mg) daily **S**
- Stopped: Ferric carboxymaltose 750 mg (15 mL vial, 50 mg/mL) by intravenous infusion, two doses two weeks apart **S**

## Guideline basis

- 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022), American Heart Association, American College of Cardiology, and Heart Failure Society of America (Circulation 2022;145(18):e895-e1032)
- 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction (2024), American College of Cardiology (J Am Coll Cardiol 2024;83(15):1444-1488)
- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023), American Heart Association and American College of Cardiology (Circulation 2023;148(9):e9-e119)
- CMID: Clinical Monitoring Intelligence Database, heart failure and ischemic heart disease monographs (2026), Aether Forge

## Follow-up

- Review in two weeks with a metabolic panel (two weeks after spironolactone), a lipid panel and the KCCQ-12. Call for lightheadedness, vomiting or diarrhea (sick-day rules), or a weight change beyond the plan. **S**
- Next scheduled visit 1957-04-27: two-week review, five days after the sick visit: kidney function and potassium, medicine doses, lipids, and cardiac rehabilitation adapted to the ocean. **S**
